Acadian Asset Management
ABOS icon

Acadian Asset Management’s Acumen Pharmaceuticals ABOS Stock Holding History

Acadian Asset Management’s Portfolio ABOS Stock Details ABOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$718K Buy
270,338
+84,488
+45% +$209K ﹤0.01% 1353
2026
Q1 		$435K Buy
185,850
+33,070
+22% +$84.4K ﹤0.01% 1398
2025
Q4 		$320K Buy
152,780
+74,860
+96% +$149K ﹤0.01% 1422
2025
Q3 		$131K Buy
+77,920
New +$108K ﹤0.01% 1469
2024
Q4 		– Sell
-18,643
Closed -$46K – 1583
2024
Q3 		$46K Buy
+18,643
New +$50.6K ﹤0.01% 1805
2024
Q1 		– Sell
-91,496
Closed -$350K – 1543
2023
Q4 		$350K Buy
+91,496
New +$272K ﹤0.01% 1113
2023
Q1 		– Sell
-15,741
Closed -$85K – 1714
2022
Q4 		$85K Buy
+15,741
New +$106K ﹤0.01% 1471

Other funds holding ABOS

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
KIA
Knollwood Investment Advisory Hunt Valley, Maryland $1.12B AUM 41.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Acadian Asset Management's ABOS Position: Q2 2026 in Review

Acadian Asset Management increased its Acumen Pharmaceuticals (ABOS) stake by 45% in Q2 2026, buying an estimated $209K and bringing the position to 270,338 shares worth $718K. The position accounts for ﹤0.01% of the portfolio, ranked #1353.

Acadian Asset Management first reported a position in ABOS in Q4 2022 and has held it in 7 quarters since. 96 funds tracked by Wall St. Rank hold ABOS as of Q2 2026.

  • Acadian Asset Management held 270,338 shares of Acumen Pharmaceuticals worth $718K as of Q2 2026.
  • Acadian Asset Management bought 84,488 Acumen Pharmaceuticals shares in Q2 2026, an estimated $209K.
  • Acumen Pharmaceuticals made up ﹤0.01% of Acadian Asset Management's portfolio in Q2 2026, its #1353 holding.
  • Acadian Asset Management first reported a position in Acumen Pharmaceuticals in Q4 2022 and has held it in 7 quarters since.
  • 96 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q2 2026.

Based on Acadian Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.